scm logo

SCM Life Science (hereinafter referred to as SCM Life Science) signed a joint research and development agreement with Allele Biotex (hereinafter referred to as Early Biotech), a biotech company based in San Diego, USA on the 20th for a 'diabetes treatment using induced pluripotent stem cell-derived pancreatic cells'.

An official said, "Induced pluripotent stem cell research is a new growth strategy for the cell therapy industry in Japan, and the government is actively supporting it, but it is an area that has not yet been activated in Korea." As a pluripotent cell with the ability to differentiate, it is expected to have high application in the field of regenerative medicine, so we would like to confirm the efficacy of diabetes treatment through this joint research using pancreatic cells."

Allele Biotech emphasizes that it has a technical advantage over "Oct3/4, Sox2, Klf4 and c-Myc," which are called factors of Professor Shinya Yamanaka of Japan, who received the Nobel Prize in Physiology and Medicine in 2012, by applying mRNA source technology to induced pluripotent stem cells.

SCM Life Science judged that Allele biotech's induced pluripotent stem cells are highly likely to be commercialized in that they are safe by using autologous cells, can be collected by simple procedures at nearby clinic institutions, transportation to manufacturing sites, and production of large-scale treatments.

In addition, Allele Biotech has its own cGMP production facility in the United States to build and differentiate induced pluripotent stem cell lines from various angles, and manages donor screening and tissue biopsy monitoring to documentation.

Lee Byung-gun, CEO of SCM Life Science, said, "We are happy to jointly promote the development of diabetes treatments using early biotech and induced pluripotent stem cells in addition to adult stem cells that we are focusing on. And he said." In addition to Coimune's immuno-cancer drug technology and cGMP facilities, we expect Allele Biotech's core technology, cGMP facilities, and operational experiences to contribute to SCM Life Science' entry into the U.S. market.

Wang Ji-wu, CEO of Allele Biotech (Dr. Wang Ji-wu), said, "I have a lot of experience in cell therapy, and I am looking forward to forming a partnership with SCM Life Science, which is an actual clinical stage." Through this opportunity, the two companies will create synergy and meaningful results in the field of induced pluripotent stem cells, he emphasized.

Meanwhile, SCM Life Science currently has a pipeline of adult stem cell therapy tailored to various refractory diseases such as chronic/acute Graft versus host disease (GVHD), severe acute pancreatitis, severe atopic dermatitis, and severe liver cirrhosis. In the future, the strategy is to leap forward as a leader in regenerative medicine through various application studies as well as mesenchymal stem cell therapy.